KLC2 knockdown from CML cells enhanced cell proliferation, decreased imatinib sensitivity, and reduced cleaved PARP-1, suggesting that KLC2 was required for the imatinib-induced apoptosis in CML cells. This evidence concerns the gene KLC2 and chronic myelogenous leukemia, BCR-ABL1 positive.